Phase 2 Crohn's Disease and Colitis Trial, Recruiting (NCT07483099)

Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT07483099 Sponsor: Eli Lilly and Company Condition: Crohn's Disease and Colitis

Printed from Voxsanity (voxsanity.com.au) — NCT07483099 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Crohns Disease And Colitis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You must meet the general eligibility requirements of the main IIBD study (except those specific to ulcerative colitis — confirm with trial site)
If you are currently taking certain weight management or diabetes medications (such as GLP-1 medications like semaglutide or similar), you may still be able to join as long as your dose has been stable and unchanged around the time of your screening appointment

Who may not be able to join:

People who have a liver disease or serious liver condition
People who have a history of any bone disease that affects how the body builds or breaks down bone (confirm with trial site)
People who, in the last 180 days (roughly 6 months), have experienced any of the following: a heart attack, a stroke, being hospitalised for severe chest pain (unstable angina), being hospitalised for heart failure, or having a procedure to restore blood flow to the heart
People who are currently taking, or who would need to take, any medications that are not allowed under the rules of this study (confirm with trial site for the full list)
People who meet any of the general exclusion criteria from the main IIBD study (except those specific to ulcerative colitis — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 30 June 2026

Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07483099

Sponsor: Eli Lilly and Company

Phase: Phase 2

Status: Recruiting

Condition: Crohn's Disease and Colitis

More information: https://clinicaltrials.gov/study/NCT07483099

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You must meet the general eligibility requirements of the main IIBD study (except those specific to ulcerative colitis — confirm with trial site)
If you are currently taking certain weight management or diabetes medications (such as GLP-1 medications like semaglutide or similar), you may still be able to join as long as your dose has been stable and unchanged around the time of your screening appointment

Who may not be able to join:

People who have a liver disease or serious liver condition
People who have a history of any bone disease that affects how the body builds or breaks down bone (confirm with trial site)
People who, in the last 180 days (roughly 6 months), have experienced any of the following: a heart attack, a stroke, being hospitalised for severe chest pain (unstable angina), being hospitalised for heart failure, or having a procedure to restore blood flow to the heart
People who are currently taking, or who would need to take, any medications that are not allowed under the rules of this study (confirm with trial site for the full list)
People who meet any of the general exclusion criteria from the main IIBD study (except those specific to ulcerative colitis — confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 30 June 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 2

Sponsor

Eli Lilly and Company

Registry

ClinicalTrials.gov

Start date

4 May 2026

Est. completion

1 June 2027

Where this trial is recruiting

🇧🇪 Belgium 🇧🇷 Brazil 🇨🇦 Canada 🇨🇳 China 🇩🇪 Germany 🇭🇺 Hungary 🇮🇱 Israel 🇮🇹 Italy 🇵🇱 Poland 🇺🇸 United States

Primary endpoints

Percentage of Participants with Crohn's Disease who Achieve Endoscopic Response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov